Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
3/A

An amendment to a 3 filing. Non-EDGAR filing

 View HTML
0001179110-16-022254.pdf
0001179110-16-022254.rtf
0001179110-16-022254.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-022256.pdf
0001179110-16-022256.rtf
0001179110-16-022256.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-004244.pdf
0001558370-16-004244.rtf
0001558370-16-004244.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-004036.pdf
0001558370-16-004036.rtf
0001558370-16-004036.xls
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0001558370-16-004066.pdf
0001558370-16-004066.rtf
0001558370-16-004066.xls
EX-101.INS - EX-101.INS
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001558370-16-004067.pdf
0001558370-16-004067.rtf
0001558370-16-004067.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-003864.pdf
0001558370-16-003864.rtf
0001558370-16-003864.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000921895-16-003392.pdf
0000921895-16-003392.rtf
0000921895-16-003392.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0001144204-16-082682.pdf
0001144204-16-082682.rtf
0001144204-16-082682.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000315066-16-004895.pdf
0000315066-16-004895.rtf